Huntington’s hurt continues
Annexon becomes the latest group to provide a confusing update in the disease.
Days of reckoning for immune checkpoint blockers
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.
Argenx’s independent streak approaches its biggest test
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Doomsday for Allakos
If lirentelimab reduces eosinophils in diseases characterised by eosinophil accumulation, why doesn’t it work?
Key big pharma catalysts to kick off 2022
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
